Latest Breaking News On - Tim sparey - Page 1 : comparemela.com

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation

VYNE Therapeutics Announces Licensing of BET Inhibitor

VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major.

VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited

Dundee University spinout company signs deal worth more than £100m

Dundee University spinout company signs deal worth more than £100m Updated: May 11, 2021, 4:15 pm © John Post. Members of the In4Derm team (from l-r) Dr Andrew Woodland, Dr Rangeetha Jayaprakash, and Dr Mark Bell. A Dundee University spinout company has signed an agreement that could be worth up to $200 million. In4Derm is an innovative drug discovery company developing the next generation of topical and oral therapies for widespread inflammatory conditions such as eczema and rheumatoid arthritis. The Dundee firm has agreed an option license agreement with an unnamed company that will bring financial and development support, and will work on the development of In4Derm’s pipeline assets.